Takeda Pharmaceuticals has
for exclusive worldwide rights to develop, manufacture and commercialize antibody-drug conjugates (ADCs) using a panel of selected Innate Pharma antibodies against an undisclosed target, with a primary focus in Celiac disease.
Under the terms of the deal, France-based Innate will receive $5 million upfront and is eligible to receive up to $410 million in future development, regulatory and commercial milestones, plus royalties on potential net sales of any commercial product resulting from the license.
Japan-based Takeda already has three
for celiac disease in phase 2 trials — TAK-101, TAK-227 andTAK-062.TAK-101, licensed from
in 2019, is an immune-modifying nanoparticle that contains gliadin proteins designed to promote immune tolerance to gluten by preventing gliadin-specific T-cell activation. TAK-227, born from a
with Zedira and Dr. Falk Pharma, isa selective, oral small molecule designed to inhibit tissue transglutaminase.TAK-062, picked up in the
of PvP Biologics, is an enzyme designed to break down gluten proteins in the stomach.
While applying ADC modalities to celiac disease is relatively new territory,ADC deals in the oncology field have been exploding.BioNTech just
with China-based biotech DualityBio to co-develop and commercialize two cancer ADC candidates.A few weeks ago,
revealed a $43 billion deal toacquire the ADC technology pioneer,Seagen. The following day, Synaffix and MacroGenics
that they had expanded their next-gen ADCs partnership.
, AstraZeneca signed a potential $1.1 billion deal withChina-based KYM Biosciencesfor a potential first-in-class ADC targeting Claudin 18.2